As of November 2025, nearly 80% (77.8%) of all Microdose GLP-1Rx users stayed engaged with the Noom app for 4 or more weeks, and D30 engagement for our December cohort was over 40% (43.6%), 1 which is at least 10 times higher than average health, medical, and fitness app retention
Current dose (mg): Tracks your escalation progress
Work with your provider to submit thorough documentation of your BMI, weight-related health conditions, and previous weight loss attempts
The controversial weight-loss drug Ozempic is a GLP-1
Severe Gastrointestinal Disease Active gastroparesis Severe inflammatory bowel disease History of pancreatitis (relative contraindication) Relative Contraindications (Use with Caution) 1
And at a fraction of the standard dose